公司概覽
業務類別 Drug Manufacturers - General
業務概覽 Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
公司地址 One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
電話號碼 +1 732 524-0400
傳真號碼 --
公司網頁 https://www.jnj.com
員工數量 138200
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Elizabeth Forminard Executive Vice President and Chief Legal Officer -- 11/02/2026
Ms. Kristen Mulholland Executive Vice President and Chief Human Resources Officer -- 11/02/2026
Mr. Timothy Schmid Executive Vice President and Worldwide Chairman, MedTech 美元 896.31K 11/02/2026
Mr. Joaquin Duato Chairman of the Board and Chief Executive Officer 美元 1.60M 11/02/2026
Mr. Joseph J. Wolk, C.P.A. Executive Vice President and Chief Financial Officer 美元 1.21M 11/02/2026
Mr. James D. Swanson Executive Vice President and Chief Information Officer -- 11/02/2026
Ms. Jennifer L. Taubert Executive Vice President and Worldwide Chairman, Innovative Medicine 美元 1.19M 11/02/2026
Ms. Kathryn E. Wengel Executive Vice President and Chief Technical Operations and Risk Officer -- 11/02/2026
Mr. Robert J. Decker, Jr Controller and Chief Accounting Officer -- 11/02/2026
Dr. John C. Reed,M.D.,PhD Executive Vice President, Innovative Medicine, R&D 美元 1.19M 11/02/2026
Ms. Vanessa Broadhurst Executive Vice President, Global Corporate Affairs -- 11/02/2026
 
董事會成員
董事會 職務 更新日期
Dr. Paula A. Johnson,M.D. Independent Director 11/02/2026
Ms. Marillyn A. Hewson Lead Independent Director 11/02/2026
Mr. Hubert Joly Independent Director 11/02/2026
Mr. Eugene A. Woods Independent Director 11/02/2026
Dr. Mary C. Beckerle, PhD Independent Director 11/02/2026
Dr. Mark B. McClellan, M.D.,PhD Independent Director 11/02/2026
Mr. Daniel Eduardo Pinto Director 11/02/2026
Mr. Joaquin Duato Chairman of the Board and Chief Executive Officer 11/02/2026
Dr. Jennifer A. Doudna, PhD Independent Director 11/02/2026
Dr. Nadja Y. West, M.D. Independent Director 11/02/2026
Mr. Mark A. Weinberger Independent Director 11/02/2026
Mr. John G. Morikis Director 11/02/2026
 
所屬ETF (更新日期: 07/03/2026 02:29)
代號 名稱 佔比% 持有日期
RGLORussell Inv Global Equity ETF0.0003%28/02/2026
CFOVictoryShares US 500 Enh Vol Wtd ETF0.0003%27/02/2026
NMAINuveen Multi-Asset Income0.0003%31/12/2025
VFVAVanguard US Value Factor ETF0.0003%31/12/2025
GVLEGoldman Sachs Value Opportunities ETF0.0003%27/02/2026
TCALT. Rowe Price Cap Apprec Prm Inc ETF0.0003%28/02/2026
FTQIFirst Trust Nasdaq BuyWrite Income ETF0.0003%26/02/2026
IQSZInvesco Global Equity Net Zero ETF0.0003%27/02/2026
UDIVFranklin US Core Dividend Tilt Index ETF0.0002%28/02/2026
BFRZInnovator Equity Managed 100 Buffer ETF0.0002%27/02/2026
CCORCore Alternative ETF0.0002%27/02/2026
NZACState Street®SPDR®MSCIACWIClmPrsAlgndETF0.0002%27/02/2026
LVDSJPMorgan Fundamental Data Sci Lrg ValETF0.0002%27/02/2026
KOOLNorth Shore Equity Rotation ETF0.0002%27/02/2026
ONOFGlobal X Adaptive US Risk Management ETF0.0002%27/02/2026
LCFTouchstone US Large Cap Focused ETF0.0002%27/02/2026
HUSVFirst Trust Hrzn MgdVolatil Domestic ETF0.0002%26/02/2026
GLOFiShares Global Equity Factor ETF0.0002%28/02/2026
DVNDTouchstone Dividend Select ETF0.0002%27/02/2026
FFNDOne Global ETF0.0002%27/02/2026
  1    2    3    4    5    6    7    8    9    10    11    12    13    14    15   16    17    18    19    20    21    22    23    24    25    26  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.